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Available online 24 February 2016Multiplex bead-based assays havemany advantages over ELISA, particularly for the analyses of large quantities of
samples and/or precious samples of limited volume. Although many commercial arrays covering multitudes of
biologically signiﬁcant analytes are available, occasionally the development of custom arrays is necessary.
Here, the development of a custom pentaplex sandwich immunoassay using Protein G-coupled beads, for anal-
ysis using the Luminex® xMAP® platform, is described. This array was required for the measurement of candi-
date biomarkers of vaccine safety in small volumes of mouse sera. Optimisation of this assay required a
stepwise approach: testing cross-reactivity of the antibody pairs, the development of an in-house serum diluent
buffer as well as heat-inactivation of serum samples to prevent interference from matrix effects. We then dem-
onstrate the use of this array to analyse inﬂammatory mediators in mouse serum after immunisation. The work
described here exempliﬁes how Protein G-coupled beads offer a ﬂexible and robust approach to develop custom
multiplex immunoassays, which can be applied to a range of analytes from multiple species.
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Serum1. Introduction
Vaccines are of global importance to public health because they are a
cheap, safe and efﬁcient means of combating infectious diseases, cancer
and chronic diseases (Nossal, 2011). In order to accelerate the develop-
ment and introduction of safer and more effective new vaccines, novel
approaches to identify and predict adverse reactions to experimental
vaccines early in the development cycle are essential (Kaufmann et al.,
2014; Rappuoli et al., 2014). Thiswill require the continued cooperation
between the pharmaceutical, academic and regulatory sectors.
BioVacSafe (Biomarkers for enhanced Vaccines immunoSafety) is an
Innovative Medicine initiative (IMI)-funded consortium consisting of
19 partner organisations from leading European industrial, regulatory
and academic institutions (www.biovacsafe.eu) (Lewis and Lythgoe,
2015). This 5-year project aims to identify biomarkers that will speed
up, improve aswell as reduce the cost of testing andmonitoring vaccine
safety, bothbefore and after release to themarket. As part of this project,
many human and animal studies are being carried out and are generat-
ing a vast number of samples for analyses. xMAP® Technology is being
employed as a high throughput approach to screen these samples for(J.U. McDonald),
r B.V. This is an open access article u
ent-licence/version/3/)multiple potential biomarkers simultaneously, especially using small
sample volumes.
The Luminex® xMAP® Technology (Houser, 2012; Vignali, 2000) is
based on microscopic (5.6 or 6.5 μm) beads, known as microspheres,
which are ﬁlled with different ratios of two or three dyes resulting in
500 unique ﬂuorescent proﬁles or bead regions for the development
of up to 500-plex assays. Analytes bound to the beads via “capture”
molecules (e.g., antibodies, antigens, oligonucleotides, enzyme sub-
strates, receptors, etc.) are detected by the reportermolecule phycoery-
thrin (PE) conjugated to streptavidin or a secondary or “detection”
molecule (e.g., antibody). Multiplexing (i.e. simultaneous detection of
many analytes in the same sample) is possible because one capture
molecule to a speciﬁc analyte is attached to a speciﬁc bead region
(i.e. a set of beads with the same ﬂuorescent proﬁle). Luminex®
analyser instruments are essentially two laser ﬂow cytometers: the
ﬁrst laser allows identiﬁcation of the bead region by excitation of the
bead dyes, whilst the second enables quantiﬁcation of the analyte
bound to the bead by excitation of the PE reporter molecule (Houser,
2012; Vignali, 2000). Analyte concentration is determined bymeasuring
the median ﬂuorescence intensity (MFI) of the reporter dye and
interpolating from the standard curve.
It is not always possible to obtain a commercial xMAP® array
that can detect all analytes of interest, and the use of multiple ELISAs
is not a viable alternative for large numbers of small volume samples.
Consequently, development of home-brew xMAP® assays is necessary.
MagPlex® Microspheres are superparamagnetic beads with a surfacender the Open Government Licence (OGL)
Table 1
Catalogue numbers and stock concentrations of R&D systems DuoSet ELISA reagents
utilised, as well as ﬁnal concentrations of the capture antibodies used to coat the Protein
G-coupled beads.
Mouse
analyte
Cat. No. Top
standard
(ng/ml)
Capture
antibody
(μg/ml)
Detection
antibody
(μg/ml)
Capture antibody
coating concentration
(μg/ml)
IL-2Ra DY2438 0.5 144 108 2.88
TREM-1 DY1187 4 144 9 2.88
IL-1Ra DY480 10 144 72 2.88
PTX3 DY2166 14 720 18 14.4
IP-10 DY466 4 360 108 7.2
CRP DY1829 1.5 360 72 7.2
sTNFRII DY4260 0.5 360 72 7.2
7J.U. McDonald et al. / Journal of Immunological Methods 433 (2016) 6–16containing 100 million carboxyl groups on each bead, which facilitate
covalent attachment of “capture” molecules during a two-step
carbodiimide reaction (Staros et al., 1986). This chemistry involves acti-
vation of the carboxyl groupswith the aid of EDC and sulfo-NHS to form
amine reactive sulfo-NHS-ester intermediates. All proteins contain pri-
mary amine groups that readily form covalent amide bonds with
activated carboxylated beads in the correct pH/ionic strength
conditions. The most popular use of carboxylated xMAP® beads is
as antibody-coupled reagents for use in sandwich immunoassays.
However, the orientation of the coupled capture antibody is random
(de Jager and Rijkers, 2006), and antibody immobilisation may mask
antigen recognition epitopes (Schwenk et al., 2007). Consequently,
only a fraction of the coupled antibodies will have the capacity to
bind ligands.
In this study, Protein G-coupled MagPlex® Microspheres were
generated as a universal reagent for the development of custom
xMAP® arrays. Protein G is a cell wall protein of group G streptococci
that binds immunoglobulins via Fc regions (Bjorck and Kronvall,
1984; Reis et al., 1984). Aside from ensuring the correct orientation
of capture antibodies, the major advantage of coupling Protein G to
xMAP® beads is the ease of producing “mix and match” bead regions
for multiplex assays without further coupling reactions. Here, we
describe the use of ELISA antibody pairs and Protein G-coupled
beads for the development of a multiplex sandwich immunoassay
for simultaneous quantiﬁcation of interleukin 2 receptor alpha
(IL-2Ra), IFN gamma inducible protein 10 (IP-10; also known as
CXCL10), C-reactive protein (CRP), interleukin 1 receptor antagonist
(IL-1Ra) and soluble Tumour Necrosis Factor Receptor II (sTNFRII) in
small volumes of mouse sera. In determining optimal procedures
for the multiplex assay, antibody cross-reactivity against Triggering
Receptor Expressed on Myeloid Cells 1 (TREM-1) and Pentraxin 3Fig. 1. Coupling and stability of Protein G on xMAP® beads. (A)MagPlex®Microspheres were c
in a carbodiimide reaction. Coupling was conﬁrmed by labelling with dilutions of PE-conjugate
≥10,000 MFI. (B) The stability of the Protein G-coupled beads was determined by comparing c(PTX3) were identiﬁed, thereby ruling out their inclusion in the array.
The analytes of interest are potential biomarkers of vaccine safety
being investigated by the IMI-JU project BioVacSafe.
2. Materials and methods
2.1. Reagents, buffers and instruments
Bead coupling reactions were carried out using recombinant
Protein G (AbD Serotec; 740601L), 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride (EDC; ThermoFisher Scientiﬁc) and
N-hydroxysulfosuccinimide (Sulfo-NHS; ThermoFisher Scientiﬁc).
Handheld tube (Life Technologies or Qiagen) or plate (MerckMillipore)
magnetic separators were used when washing magnetic beads.
Luminex analyses were carried out using a Bio-Plex®/LiquiChip 100
(Bio-Rad or Qiagen) instrument.
R&D systems Duoset® ELISA kits containing standards, capture
antibodies and biotinylated detection antibodies (Table 1) were
utilised. Also employed were biotinylated rabbit anti-Protein
G (Abcam; ab7251), Streptavidin-PE (eBioscience; 12-4317-87,
BD Pharmingen; 554,061, or Biolegend; 405245) as well as PE-
conjugated species-speciﬁc secondary antibodies: anti-hamster IgG
(R&D Systems; F0120), anti-goat IgG (R&D Systems; F0107) and
anti-rat IgG (R&D Systems; F0105B). Commercial buffers utilised
were General serum diluent (ImmunoChemistry Technologies;
647), Plasma sample diluent (ImmunoChemistry Technologies;
694) and Neptune diluent (ImmunoChemistry Technologies; 6124).
The following buffers were also prepared: activation buffer [0.1 M
Monobasic Sodium Phosphate, pH 6.2], PBS [pH 7.4; containing
138 mM NaCl, 2.7 mM KCl], PBS-TBN# [PBS, 0.1% IgG-free BSA
(Jackson ImmunoResearch), 0.02% Tween-20, 0.05% Azide], PBS-
BN# [PBS, 1% IgG-free BSA, 0.05% Azide], PBS-BSA [PBS, 1% BSA] and
J Buffer [PBS, 20 mM Tris–HCl, 1% Goat Serum, 1% Sheep Serum,
0.05% Tween-20]. In addition, bovine serum albumin (BSA), foetal
bovine serum (FBS; Gibco), normal mouse serum, non-fat dried
milk powder (Panreac Applichem) and Tween-20 were employed
as blocking agents in PBS, where appropriate. All buffers were
ﬁlter-sterilised and stored at 4 °C. Unless otherwise stated, buffer
reagents were obtained from Sigma Aldrich.
2.2. Coupling Protein G to MagPlex® microspheres
Protein G used in the coupling reactions was free of sodium azide,
BSA, glycine, Tris and amine-containing additives. Prior to use,
all buffers were brought to room temperature, EDC and Sulfo-NHS
were desiccated at room temperature for approximately 1 h, andonjugated to varying amounts of Protein G, ranging from 1 to 125 μg per 1.25 × 106 beads,
d rabbit anti-Protein G antibody. Optimal coupling is achieved when the curve saturates at
oupling conﬁrmations carried out 1 day or 17 months post coupling.
8 J.U. McDonald et al. / Journal of Immunological Methods 433 (2016) 6–16MagPlex® Microspheres (Bio-Plex Pro™ Magnetic COOH Beads;
Bio-Rad; MC100XX) were vortexed for 30 s then sonicated for 15 s.
For a 1× scale coupling reaction, 1.25 × 106monodisperse carboxylated
beads were washed and resuspended in 80 μl of activation buffer. USAFig. 2. Optimal capture antibody coating of Protein G-coupled beads. To determine optimal coa
incubated with varying dilutions (ranging from 0.8 to 14.4 μg/ml; refer to Table 1) of 7 differ
species-speciﬁc antibodies in singleplex xMAP® assays. Optimal capture antibody coating g
7.2 μg per 2.5 × 105 beads) was deemed to be suitable for all capture antibodies investigated.Scientiﬁc co-polymer microcentrifuge tubes (Cat No. 1415–2500)
were used to prevent loss of beads resulting from sticking to the walls
of microcentrifuge tubes. Sulfo-NHS then EDC (50 mg/ml in activation
buffer; 10 μl of each) was added to the beads, followed by 20 minting amounts for the proposed array, different Protein G-coupled bead regions were each
ent capture antibodies. These were detected by varying concentrations of PE-conjugated
enerates a curve that saturates above 10,000 MFI. A 1:50 dilution (ranging from 1.44 to
9J.U. McDonald et al. / Journal of Immunological Methods 433 (2016) 6–16incubation. Activated beads were washed twice using 150 μl PBS, and
then coupled with 1 to 125 μg Protein G in 500 μl PBS for 2 h. Coupled
beads were washed with 500 μl PBS then blocked in 250 μl PBS-TBN#
for 30 min. Beads were washed and stored in PBS-BN# at 4 °C in theFig. 3. Comparison of antibody pair performance in xMAP® vs ELISA. Standard curves genera
standard concentrations ranging from 0.5 to 14 ng/ml recommended by the manufacturer f
dilution series were too low for xMAP® analysis. Consequently, the top standard concentrat
8-point 3-fold dilution series were used to test all 7 antibody pairs by ELISA (C).dark. The bead concentration was determined using an Invitrogen
Countess® Automated Cell Counter. All incubations were carried out
in the dark at room temperature with continuous mixing. Washing
steps involved 1 min recovery of beads using a magnetic separator.ted for all 7 analytes using the xMAP® technology (A, B). In singleplex assays (A [i]), top
or ELISA were utilised (refer to Table 1). Low MFIs and curve shapes indicated that the
ion was increased to 125 or 250 ng/ml for multiplex assays (A [ii] and B). These revised
10 J.U. McDonald et al. / Journal of Immunological Methods 433 (2016) 6–162.3. Coupling conﬁrmation and stability
Two-fold serial dilutions of biotinylated rabbit anti-Protein G
antibody were mixed with 5000 beads per well of a 96-well plate. The
ﬁnal antibody concentration, in a total volume of 50 μl PBS-BN#, ranged
from 0.0625 to 4 μg/ml. As a negative control, beads mixed with PBS-
BN# were also included. The plate was incubated for 30 min, and
beads were washed thrice in 100 μl PBS-BN#. Then 50 μl streptavidin-
PE (2 μg/ml in PBS-BN#) was added to beads and incubated for
10 min. Beads were washed thrice then resuspended in 125 μl PBS-
BN#. After a 30 s incubation at 1100 rpm on a plate shaker, 50 to 75 μl
beads fromeachwell was analysed on a Luminex® analyser instrument,
according to the system manual. In general, coupling should yield at
least a MFI of 10,000 (at standard PMT settings on Luminex® 200™
and FLEXMAP 3D® instruments or on a MAGPIX® instrument) at
saturation for optimal use in immunoassays. The process was repeated
in determining the stability of the Protein G-coupled beads after storage
at 4 °C for over a year. All incubations were carried out at room temper-
ature in the dark on a plate shaker at ~800 rpm, unless otherwise stated.
Washing steps involved 1 min recovery of beads using a magnetic
separator.2.4. Coating Protein G-coupled beads with capture antibody
For the chosen bead region per analyte, 2.5 × 105 Protein G-coupled
beads were incubated with varying dilutions (1:25 to 1:180) of captureFig. 4. Cross-reactivity of antibody pairs inmultiplex sandwich immunoassays. xMAP® assaysw
concentration of 125 or 250ng/ml)was individually tested against the bead cocktail. Black bars i
in the graph (and percentage values in the table) denote cross-reactivity. Cross-reactivity is d
ligand, and is represented as grey regions in the table.antibody in 500 μl PBS for 2 h at room temperature, or overnight at 4 °C.
(Refer to Table 1 for stock concentrations of the capture antibodies).
Beads were washed twice and blocked with 500 μl PBS-BSA for 1 h.
(Any unoccupied IgG-binding domains of the coupled Protein G were
occupied by immunoglobulins within the BSA). Following two washes,
beads were resuspended in 500 μl PBS-BSA. Once coated with capture
antibody, the beads could be stored in the dark at 4 °C for a maximum
of 4 days. To determine the optimal dilution of capture antibody to
be used, 5000 antibody-coated beads were labelled with two-fold serial
dilutions of PE-conjugated species-speciﬁc secondary antibody (0.0625
to 4 μg/ml in PBS-BSA) per well of a 96-well plate for 1 h. After two
washes in PBS-BSA, beads were resuspended in 100 μl PBS-BSA, mixed
for 5min to prevent aggregation, then analysed on a Luminex®analyser
instrument. A capture antibody dilution that saturated (or was on the
way to saturation) between 10,000 and 20,000 MFI was chosen. All
incubations were carried out at room temperature in the dark with
agitation, unless otherwise stated. Washing steps involved 1 min
recovery of beads using a magnetic separator.2.5. xMAP® sandwich immunoassays
Per well, 25 μl sample was mixed with 25 μl antibody-coated beads;
5000 beads per analytewas used. The platewas incubated for 2 h. Beads
were washed twice then incubated with 50 μl biotinylated detection
antibody (1:500 dilution; Table 1) for 2 h. After two washes, beads
were incubated with 50 μl streptavidin-PE (5 μg/ml) for 30 min. Beadsere carried out using a cocktail of antibody-coated beads. Each analyte (at the top standard
n the graph (and black regions in the table) denote speciﬁc antibody recognition. Grey bars
etermined to be an off-target reactivity that was ≥5% of the MFI observed for the cognate
11J.U. McDonald et al. / Journal of Immunological Methods 433 (2016) 6–16were washed twice, resuspended in 100 μl PBS-BSA, agitated for 5 min
to prevent aggregation then analysed on an analyser instrument.
The MFI of PE was determined for each bead region in each well.Fig. 5. J Buffer reduces serum matrix effects. Multiplex xMAP® assays were carried out to test
buffers (B) as possible serum sample diluent. Where appropriate, 20% normal mouse se
various diluents or 100% normal mouse serum at the top standard concentration of 125 o
determine signiﬁcance (*P b 0.05).Four-parameter logistic curves were generated using GraphPad Prism.
All incubations were carried out in clear-bottom, black 96-well plates
(Bio-Rad) at room temperature in the dark on a plate shaker. PBS-BSAPBS containing a variety of common blockers (A) or alternative (commercial or in house)
rum (MS) was also included in the diluent buffers. Each analyte was spiked in the
r 250 ng/ml. One way anova with Dunnett's multiple comparison tests were used to
Fig. 6.Heat inactivation reduces serummatrix effects. Analytes in J Buffer (JB) spikedwith
20% normal mouse serum were tested against a cocktail of antibody-coated beads using
the xMAP® technology. Control or heat inactivated (HI) normalmouse serumwasutilised.
12 J.U. McDonald et al. / Journal of Immunological Methods 433 (2016) 6–16served as wash buffer and reagent diluent. Washing steps involved
1 min recovery using a magnetic separator.
The samples used were commercial protein standards diluted
in PBS-BSA or a variety of different buffers (Section 2.1). Where appro-
priate, normal mouse serum heat-inactivated at 56 °C for 30 min was
used. Experiments generating standard curves involved an eight point
standard curve using three-fold serial dilutions in PBS-BSA. Initial assays
utilised the top standard concentrations recommended for the R&D sys-
tems DuoSet ELISA kits (Table 1). Subsequently, a 250 to 0.1143 ng/ml
dilution series was carried out for all analytes except IL-2Ra, which
was diluted from 125 to 0.0571 ng/ml. Multiplex assays involved pre-
mixing an equal number of each antibody-coated bead region in PBS-
BSA. In addition, detection antibodies were pre-mixed in PBS-BSA to
achieve a ﬁnal dilution of 1:500 each (Table 1); 50 μl of this antibody
cocktail was incubated with each well of beads. To determine whether
antibody pairs cross-reacted with non-cognate ligands in multiplex as-
says, pre-mixed antibody-coated beads were incubated with each ana-
lyte in different wells of a 96-well plate. The top standard
concentration (125 or 250 ng/ml) was used for all analytes. PE signal
was generated by incubation with the detection antibody cocktailFig. 7. Reproducibility and reliability of the custom pentaplex assay. Intra-assay (A: 3 experime
showing mean CV ± standard error of mean. The mean and standard error values are displayethen streptavidin-PE. Cross-reactivity was determined to be off-target
reactivity that was ≥5% of the MFI observed for the cognate ligand.2.6. Sandwich ELISA
ELISAs were carried out using R&D Systems DuoSet kits according to
the manufacturer's protocol, except for one deviation. Brieﬂy, wells of a
96-well plate were coated with capture antibody (1:180 dilution;
Table 1) overnight at room temperature. After three washes, wells
were blocked in PBS-BSA for a minimum of 1 h. This was followed by
three washes, then incubation with sample or standard for 2 h at
room temperature. In deviation from the manufacturer's protocol, the
top standard concentration for the eight-point three-fold serial dilution
was 125 ng/ml for IL-2Ra and 250 ng/ml for the remaining analytes.
Wells were washed then incubated with biotinylated detection anti-
body (1:180 dilution; Table 1) for 2 h at room temperature. The wells
were washed then incubated with Streptavidin-HRP for 20 min at
room temperature. After a ﬁnal wash, wells were incubated with TMB
substrate solution for 1 to 2 min at room temperature. The reaction
was stopped by the addition of stop solution. Optical density of each
well was measured using a microplate reader. Four-parameter logistic
standard curves were generated using GraphPad Prism.2.7. Mice
6 to 8 week old female CB6F1 mice (Harlan Ltd., Stamford Bridge,
UK) were kept in speciﬁc-pathogen-free conditions in accordance
with the United Kingdom's Home Ofﬁce guidelines. All work was
approved by the Animal Welfare and Ethical Review Board (AWERB)
at Imperial College London. Mice were immunised intramuscularly
with non-adjuvanted or MF59-adjuvanted trivalent subunit vaccine
(Novartis Vaccines, Italy) at one-tenth of the human dose (~1.5 μg
haemagglutinin) in a total of 100 μl (i.e. 50 μl per thigh muscle). Tail
bleedswere taken at 0, 4, 6, 12, 24, 48, 72 and 144 h post immunisation.
At each time point, blood drawswere taken from 5 of 20mice; different
mice were used at each time point to reﬁne animal usage. The blood
samples were allowed to clot for 30 min on ice and sera were extracted
by spinning at 13,680 ×g for 10 min. Sera samples were then analysed
using the custom pentaplex xMAP® array.nts) and inter-assay (B: 7 experiments) variations were calculated and plotted on a graph
d in the table.
Fig. 8. Evaluation of serum biomarker responses to adjuvanted and non-adjuvanted
inﬂuenza vaccine using custom pentaplex array. Mice were immunised intramuscularly
with non-adjuvanted or MF59-adjuvanted trivalent subunit vaccine in a total
of 100 μl. Tail bleeds were taken at 0, 4, 6, 12, 24, 48, 72 and 144 h post
immunisation. Sera from each time point were analysed using pentaplex xMAP®
array for IL-2Ra, IP-10, CRP, IL-1Ra and sTNFRII. Data points represent the mean of
n = 5 mice ± SD.
13J.U. McDonald et al. / Journal of Immunological Methods 433 (2016) 6–162.8. Statistical analysis
The coefﬁcient of variation (CV) was calculated by dividing the
standard deviation of a population by its mean then multiplying
by 100 to give a percentage. Intra-assay variation within a plate was
determined by assaying triplicates of 17 samples. Inter-assay variation
(i.e. assay-to-assay variation) was assessed by testing triplicates of 4
samples in seven separate assay runs, run on seven different days.
Mean and Standard Error of theMean (SEM) for the CVswere calculated
using GraphPad Prism. Statistical signiﬁcance was determined via one
way Anova with Dunnett's multiple comparisons test and calculated
using GraphPad Prism.
3. Results
3.1. Protein G-coupled MagPlex® microspheres are stable for N1 year
In general, bead-based sandwich immunoassays involve conjugating
capture antibodies to the solid surface via a carbodiimide reaction. Since
amine groups in antibodies are cross-linked to carboxylic acids on the
beads, the orientation of the capture antibody is unknown. Protein G
is a streptococcal cell wall protein with two IgG-binding domains
(Bjorck andKronvall, 1984; Reis et al., 1984), aswell as sites for albumin
and cell surface binding (Akerstrom et al., 1987; Bjorck et al., 1987).
Conjugating ProteinG to beads generates a reagent that ensures optimal
orientation of capture antibodies in xMAP® immunoassays, and allows
the development of multiple types of assays with the same set of beads.
To determine optimal coupling conditions, MagPlex® Microspheres
(which are 6.5 μm magnetic carboxylated beads) were conjugated to
various amounts of Protein G with the aid of EDC and Sulfo-NHS.
Recombinant Protein G lacking the albumin and cell surface binding
domains was utilised in order to reduce non-speciﬁc binding. Optimal
coupling was achieved with as little as 1 μg per 1.25 × 106 beads,
as demonstrated by a saturating MFI of ~25,000 when labelling with
biotinylated anti-Protein G antibody and Streptavidin-PE (Fig. 1a).
17 months after bead conjugation, a reduction in MFI was observed
at the lower anti-Protein G antibody concentrations, (Fig. 1b).
Nevertheless, a saturating MFI of ~25,000 was achieved at the
highest antibody concentrations. Altogether, the data indicate that
the Protein G present on the beads over a year post coupling was
still optimal for the intended purpose.
3.2. Use of Protein G-coupled beads in multiplex sandwich immunoassays
A multiplex bead array to measure IL-2Ra, TREM-1, IL-1Ra, PTX3,
IP-10, CRP and sTNFRII in mouse sera was required. As a result, seven
bead regions were coupled with Protein G. To determine the optimal
amount of each capture antibody, Protein G coupled beads were coated
with various antibody dilutions (resulting in concentrations ranging
from 0.8 to 14.4 μg/ml) then detected by PE-conjugated species-
speciﬁc secondary antibody. For all analytes except PTX3 and IP-10,
curves saturating at a MFI N10,000 were generated for the highest
antibody dilution of 1:180 (Fig. 2). To achieve the same criteria,
a 1:50 dilution was necessary for the PTX3 and IP-10 capture
antibodies (Fig. 2). A 1:50 dilution, which equates to concentrations
ranging from 2.88 to 14.4 μg/ml (Table 1), was chosen for coating
Protein G-coupled beads. Consequently, the chosen coating amount
for each capture antibody per 2.5 × 105 beads (in 500 μl antibody
solution) was as follows: (i) 1.44 μg for IL-2Ra, TREM-1 and IL-1Ra,
(ii) 3.6 μg for IP-10, CRP and sTNFRII, (iii) 7.2 μg for PTX3. Once
coated, beads were stable for use within 4 days of storage at 4 °C in
the dark.
Antibody-coated beads were ﬁrst tested for use in singleplex
sandwich immunoassays. Standard curves could be generated for
IL-2Ra, TREM-1, IL-1Ra and PTX3, but not for IP-10, CRP and sTNFRII
(Fig. 3a[i]). However, the data indicated that the eight-point three-fold
14 J.U. McDonald et al. / Journal of Immunological Methods 433 (2016) 6–16dilution series recommended by the manufacturer for ELISA (Table 1)
involved concentrations at the bottom of the standard curve. Conse-
quently, higher top standard concentrations were chosen: 125 ng/ml
for IL-2Ra and 250 ng/ml for the remaining analytes (Fig. 3a[ii]).
All antibody-coated bead regions were pre-mixed then used in multi-
plex sandwich immunoassays. Good standard curves with a wide
dynamic range covering ~3 log10were generated for all analytes except
TREM-1 and PTX3 (Fig. 3b). Use of these antibody pairs and top
standard concentrations (i.e. 125 or 250 ng/ml) in ELISA generated
good standard curves for all analytes (Fig. 3c).
3.3. Anti-TREM-1 and anti-PTX3 antibodies exhibit off-target reactivity
The inability to generate good standard curves for TREM-1 and PTX3
in themultiplex xMAP® assay indicated that the anti-TREM-1 and anti-
PTX3 antibodies were cross-reacting with non-cognate ligands.
No cross-reactivity was observed in ELISAs; the antibody pairs only
bound their speciﬁc ligands (data not shown). To investigate antibody
cross-reactivity in the multiplex assay, pre-mixed beads were tested
against each analyte individually at the top standard concentration.
Cross-reactivity was determined to be an off-target reactivity that was
≥5% of the MFI observed for the cognate ligand. All antibody-coated
beads bound to TREM-1 to varying degrees, with the greatest effect
seen with anti-PTX3 beads (Fig. 4). The increase in MFI observed
for the anti-IL-1Ra and anti-IP-10 antibody pairs were just below the
aforementioned cross-reactivity criteria. Cross-reactivity was also
observed between anti-TREM-1 and IP-10, as well as anti-sTNFRII andFig. 9. Flow chart of multiplex array development using Protein G-coupled beads. A brief
overview of the steps that are required and need to be optimised in order to develop
custom xMAP® arrays.PTX3. Consequently, TREM-1 and PTX3 detection were removed from
the array. The resulting custom pentaplex array generated was for
measurement of murine IL-2Ra, IP-10, CRP, IL-1Ra and sTNFRII.
3.4. Optimal sample preparation for custom pentaplex xMAP® assay
The custom bead array was for the measurement of ﬁve analytes in
small volumes of mouse sera. Serum is a complex mix of proteins that
may non-speciﬁcally bind to microspheres – known as matrix effects
(Elshal and McCoy, 2006). These matrix effects can interfere with the
performance of a xMAP® assay and may be observed as poor bead re-
covery, instrumentation clogging, low signals, or variable results. This
can be overcome by sample dilution using an appropriate buffer. Typi-
cally, serum is diluted at least 1:5 to reduce non-speciﬁc reactivity re-
sponses (de Jager et al., 2005). In order to investigate serum matrix
effects aswell as identify a suitable sample diluent buffer, the pentaplex
arraywas tested against protein standards diluted in a variety of buffers
in the presence or absence of normal mouse serum.Where appropriate,
20% normal mouse serumwas used to mimic the matrix that would be
encountered in diluted ex vivo experimental samples.
Detection of cognate ligands by all antibody-coated beads (except
anti-sTNFRII beads) was signiﬁcantly impaired (P b 0.0001) in the
presence of 20% normal mouse serum, compared to detection in PBS
only containing 1% BSA (Fig. 5a). Use of the following blockers
failed to alleviate the matrix-mediated interference: BSA (0.1–1%), FBS
(0.1–1%), milk (0.1–1%) and 0.05% Tween 20 (Fig. 5a). Serum matrix
effects were then investigated in three commercial diluent buffers as
well as an in-house recipe (J Buffer). J Buffer is PBS containing 20 mM
Tris–HCl, 0.05% Tween-20, 1% Goat Serum and 1% Sheep Serum. For all
antibody-coated beads (except anti-CRP), commercial diluent buffers
containing 20% normal mouse serum interfered with the detection of
cognate ligands (Fig. 5b). Only J Buffer consistently exhibited limited
interference from serum matrix effects. To enhance the effectiveness
of J Buffer, the effect of serum heat inactivation was investigated. Heat
inactivation signiﬁcantly increased (P b 0.05) detection of all analytes
(except IL-1Ra) in serum-containing J Buffer (Fig. 6); indicating
that the cause of interference was a heat labile molecule (such as
complement). IL-1Ra detection was notably increased but this was not
statistically signiﬁcant.
3.5. Inter- and intra-assay variation
The coefﬁcient of variation (CV) is a statisticalmeasure of the disper-
sion or variability of a population. In this instance, it was used to
measure the precision and reproducibility of the custom pentaplex
sandwich immunoassay. The intra-assay CV (Fig. 7a) speciﬁcally mea-
sures the accuracy of replicates within one assay, while the inter-assay
CV (Fig. 7b) measures the reproducibility of the assay on multiple
occasions. The CVs for all ﬁve analytes were low; intra-assay variation
ranged from 4.12 to 7.43% whilst the inter-assay variation was 3.77
to 11.23%. According to the FDA Bioanalytical Method Validation
guidelines, intra-assay CV of b10% and inter-assay CV of b20% are
usually acceptable.
3.6. Analyses of sera from vaccinated mice using the pentaplex array
The pentaplex xMAP® array described here was speciﬁcally devel-
oped to analyse systemic biomarker changes in response to inﬂuenza
vaccination in CB6F1 mice, using very small amounts of serum (20 μl).
Micewere immunised with non-adjuvanted or MF59-adjuvanted triva-
lent subunit inﬂuenza vaccine. Of the ﬁve analytes investigated, three
were detected in mouse sera; with IP-10, CRP and IL-1Ra being
up-regulated post immunisation (Fig. 8). These data are consistent
with previously published reports that show an increase in IP-10 and
IL-1Ra expression in response to MF59 (Caproni et al., 2012; Mosca
et al., 2008; Seubert et al., 2008), as well as increased CRP and IP-10
15J.U. McDonald et al. / Journal of Immunological Methods 433 (2016) 6–16expression in response to inﬂuenza vaccination (Christian et al., 2011;
Nakaya et al., 2011; Obermoser et al., 2013). IL-2Ra and sTNFRII
remained at baseline levels in the serum, with no difference observed
between the adjuvanted and non-adjuvanted animals in response to
intramuscular immunisation.
4. Discussion
A plethora of commercial bead array formats are available, but
the development of custom arrays is still necessary to support research
activities. This is of particular importance for scientists utilising experi-
mental animalmodels forwhich research reagents are rare; research ac-
tivities centred around the ferret model is a notable example. In this
study, we demonstrate one approach to develop custom xMAP® arrays
using Protein G-coupled beads (summarised in Fig. 9). Use of Protein G
means that (i) only one coupling procedure is necessary and (ii) capture
antibodies are orientated in the correct manner. In addition, Protein G-
coupled beads offer ﬂexibility and robustness that make it possible to
easily expand an array, and to do so within a wide time frame
(N1 year) due to the stability of this reagent. Optimal ProteinG coupling,
capture antibody coating, sample preparation and diluent for the simul-
taneous analysis of ﬁve analytes in mouse serum samples using the
xMAP® technology are demonstrated here. The analytes of interest
are potential biomarkers of vaccine safety being investigated by the
IMI-JU project BioVacSafe: soluble cytokine receptors sTNFRII and IL-
2Ra, pattern recognition receptor CRP, antagonist IL-1Ra and chemokine
IP-10. We demonstrate that the custom pentaplex array can be used to
measure these mediators in the serum of immunised mice.
The xMAP® technology has many advantages over ELISA (de
Jager and Rijkers, 2006; Houser, 2012); one of which is the require-
ment for signiﬁcantly reduced sample volume. Typically, 25 μl of
sample (or standard) is required per well of a 96-well plate, whilst
50–100 μl/well is used for each ELISA needed. Indeed, the pentaplex
bead-based sandwich immunoassay described here requires 25 μl/well
of sample/standard compared with a total of 500 μl for ﬁve ELISAs.
Since a 1:5 dilution of mouse serum was required for the pentaplex
array, this is equates to measuring 5 analytes using just 5 μl of serum in
one well. This is of particular importance because this array was devel-
oped for the analysis of sera from neonatal, as well as adult and aged
mice. ELISA also consumes relatively large volumes of reagents in com-
parison to the xMAP® technology. Typically, 100 μl/well of diluted detec-
tion antibody and streptavidin is needed per ELISA, whilst the xMAP®
technology requires a total of 50 μl/well of each reagent regardless of
the number of analytes to be investigated. Typically, 100 μl/well of dilut-
ed capture antibody is used in ELISA. For the custom pentaplex xMAP®
array described here, only 12.5 μl/well of diluted capture antibody was
needed to coat each Protein G-coupled bead region utilised. This means
that xMAP® not only utilises signiﬁcantly less reagent volumes, the
total reagent amount required is also signiﬁcantly reduced, especially
with the use of Protein G-coupled beads. Consequently, there are signif-
icant cost and sample savings associated with using xMAP® instead of
ELISA, particularly with regards to antibodies. Simultaneous analyte
measurement also greatly reduces the amount of time and labour
required to analyse large quantities of samples, thereby resulting in
higher throughput. In addition, multiplex assays ensure that all analytes
of interest are measured under the same conditions (i.e., same operator,
identical incubation times and temperatures, etc.), which is of particular
importance if a scientiﬁc question relies on a combination of biomarkers
or the relationships between them (Lewczuk, 2012). Furthermore,
bead-based assays can detect raw imprecision of repeated (duplicate)
measurements (Lewczuk, 2012), and also offer improved imprecision
because multiple, independent measurements (typically 50–100) are
carried out within each bead region (Ellington et al., 2010).
It cannot be assumed that reliable singleplex assays can automatical-
ly be converted into a reliable multiplex array. Rather, this transition
requires the development of optimal bead coupling procedures foreach capture antigen required, as well as optimisation of the assay.
Factors that can interfere with the development of multiplex assays
include antibody cross-reactivity and assay diluents (de Jager
and Rijkers, 2006; Ellington et al., 2010). It is well reported that
antibody cross-reactivity to non-target proteins is ubiquitous and
widespread. For xMAP®, the use of antibody/bead mixtures and ag-
itation means that cross-reactivity against (i) analytes, (ii) capture
antibodies, (iii) detection antibodies can occur. The references cited
here, as well as the Luminex® cookbook (http://info.luminexcorp.
com/xmap-cookbook-2nd-edition-free-download), provide helpful
guidance and protocols on how to detect and avoid cross-reactivity
when developing custommultiplex assays. The soluble pattern recogni-
tion receptor PTX3 and immunoglobulin-like receptor TREM-1 were
eliminated from the panel of interest in this study due to antibody
cross-reactivity issues detected by xMAP® but not by ELISA. This
indicates that the presentation of antigenic epitopes on microspheres
is different from that in ELISA, as has been previously reported (Khan
et al., 2006). Expansion of the array to a heptaplex might be possible if
screening of alternative PTX3 and TREM-1 antibody pairs (i.e. from
different hybridoma clones) identiﬁes reagents with minimal cross-
reactivity. Further differences between ELISA and xMAP® used in this
study were highlighted by the slightly decreased sensitivity of xMAP®
analysis for IP-10 compared to ELISA; this scenario is not unusual.
Khan et al. suggest that the availability and accessibility of the antigenic
epitopes may be limiting due to the smaller surface area of xMAP®
microspheres, whilst the concentration of antigenic molecules may
not be limiting due to the larger available surface areas in ELISA
microtitre plate wells (Khan et al., 2006).
In conclusion, the multiplex sandwich immunoassay described here
is a rapid, simple, speciﬁc, reproducible and adaptable method for the
analysis of small volumes of serum samples.
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